Intellia Therapeutics (NTLA) Non-Current Deffered Revenue (2015 - 2025)

Intellia Therapeutics (NTLA) has 11 years of Non-Current Deffered Revenue data on file, last reported at $12.5 million in Q3 2025.

• Non-Current Deffered Revenue for Q3 2025 came in at $12.5 million, down 44.53% year-over-year; the trailing twelve-month figure through Sep 2025 was $12.5 million (down 44.53% YoY), and the FY2024 annual result was $18.3 million, down 53.01% from the prior year.
• Non-Current Deffered Revenue held at $12.5 million in Q3 2025 per NTLA's latest filing, from $12.5 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $63.5 million in Q4 2021 and troughed at $12.5 million in Q2 2025.
• A 5-year average of $29.6 million and a median of $25.7 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2023: Non-Current Deffered Revenue surged 251.99% in 2021, then tumbled 71.99% in 2023.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $63.5 million in 2021, then sank by 68.6% to $19.9 million in 2022, then surged by 94.93% to $38.9 million in 2023, then slumped by 53.01% to $18.3 million in 2024, then sank by 31.32% to $12.5 million in 2025.
• Business Quant data shows NTLA's Non-Current Deffered Revenue at $12.5 million in Q3 2025, $12.5 million in Q2 2025, and $13.2 million in Q1 2025.